M. Ehlers

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Mario R W Ehlers, M. R. Ehlers, Mario Ehlers, M. R.w. Ehlers, Mario R. Ehlers, Mario Rw Ehlers, Mario R.w. Ehlers, Mario R. W. Ehlers, M. R. W. Ehlers, Mario R Ehlers, M R Ehlers, M.r.w. Ehlers
Publication record
87 papers · 4,413 citations · H-index 31

PAPERS

INHIBITION OF ACE C-DOMAIN AND NEPRILYSIN AS A NEW THERAPY IN HYPERTENSION
20210 citationsauthor #10
Alpha‐1 antitrypsin treatment of new‐onset type 1 diabetes: An open‐label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics
201824 citationsauthor #2
Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables
201825 citationsauthor #4
Who let the dogs out? The ever-present threat of autoreactive T cells
201812 citationsauthor #1
Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs
201731 citationsauthor #10
Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
201774 citationsauthor #4
Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy
201727 citationsauthor #8
OriginalClinicalScienceçGeneral Anti-Gal and Anti-Neu 5 Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs
20171 citationsauthor #10
Immune Interventions to Preserve Beta Cell Function in Type 1 Diabetes
20167 citationsauthor #1
Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.
201622 citationsauthor #6
Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial
201684 citationsauthor #16
Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes
20164 citationsauthor #3
Changes in T‐cell subsets identify responders to FcR‐nonbinding anti‐CD3 mAb (teplizumab) in patients with type 1 diabetes
201665 citationsauthor #7
Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes
2016209 citationsauthor #7
Strategies for clinical trials in type 1 diabetes.
201623 citationsauthor #1
A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice
201535 citationsauthor #15
Targeting Memory T Cells in Type 1 Diabetes
201539 citationsauthor #1
2. Durable Efficacy of Alefacept in New-Onset Type 1 Diabetes: Evidence for Lasting Modulation of Effector and Regulatory T Cells (231-OR)
20150 citationsauthor #27
Immune interventions to preserve β cell function in type 1 diabetes
201517 citationsauthor #1
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
2015252 citationsauthor #27
Restoring the balance: immunotherapeutic combinations for autoimmune disease
2014101 citationsauthor #2
Targeted immune interventions for type 1 diabetes: not as easy as it looks!
201425 citationsauthor #2
Immune-modulating effects of alpha-1 antitrypsin
2014112 citationsauthor #1
Dose response of continuous subcutaneous infusion of recombinant glucagon‐like peptide‐1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus
201413 citationsauthor #3
DB130345 3766..3774
20130 citationsauthor #3
C domain-selective inhibition of angiotensin-converting enzyme
201313 citationsauthor #1
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
2013157 citationsauthor #27
Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice
201335 citationsauthor #17
Targeting effector memory T cells with alefacept in new onset type 1 diabetes: 12 month results from the T1DAL study
201318 citationsauthor #27
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
2013133 citationsauthor #17
Anti-cytokine therapies in T1D: Concepts and strategies.
201367 citationsauthor #2
Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial
2013305 citationsauthor #3
Shedding the load of hypertension: the proteolytic processing of angiotensin-converting enzyme.
201216 citationsauthor #1
Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function
2012315 citationsauthor #13
Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience.
201215 citationsauthor #1
Synthesis of ( lS )-N-( 1-carboxy-5-aminopentyl )-glycylglycine-a prospective competitive inhibitor for angiotensin-converting enzyme
20120 citationsauthor #1
Dose response of subcutaneous GLP‐1 infusion in patients with type 2 diabetes
201123 citationsauthor #5
Vasopeptidase inhibition: Solving the cardiovascular puzzle?
20115 citationsauthor #2
Angiotensin-Converting Enzyme - New Insights into Structure, Biological Significance and Prospects for Domain-Selective Inhibitors
200916 citationsauthor #4
Pacific biomarkers, inc.
20081 citationsauthor #1
Biochemical Markers of Rheumatoid Arthritis and Osteoarthritis: Clinical Utility and Practical Considerations
20083 citationsauthor #1
Identification of C to T mutation at position −236 bp in the humanNRAMP1 gene promoter
200710 citationsauthor #7
Safety issues associated with the use of angiotensin-converting enzyme inhibitors
200616 citationsauthor #1
Homologous substitution of ACE C-domain regions with N-domain sequences: effect on processing, shedding, and catalytic properties
200620 citationsauthor #6
The N domain of somatic angiotensin-converting enzyme negatively regulates ectodomain shedding and catalytic activity.
200541 citationsauthor #5
Deletion of the cytoplasmic domain increases basal shedding of angiotensin-converting enzyme.
20046 citationsauthor #4
Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium.
2003102 citationsauthor #2
Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes.
200335 citationsauthor #5
Ace revisited: A new target for structure-based drug design
2003313 citationsauthor #4
Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
20038 citationsauthor #1
Deglycosylation, processing and crystallization of human testis angiotensin-converting enzyme.
200366 citationsauthor #4
Defining the boundaries of the testis angiotensin I-converting enzyme ectodomain.
200215 citationsauthor #4
Mycosin-1, a subtilisin-like serine protease of Mycobacterium tuberculosis, is cell wall-associated and expressed during infection of macrophages
200263 citationsauthor #4
Roles of the juxtamembrane and extracellular domains of angiotensin-converting enzyme in ectodomain shedding
200119 citationsauthor #4
Hibernating myocardium and treatment of diabetic cardiomyopathy with gpl-1 peptide.
20010 citationsauthor #1
Recombinant human GHRH(1-44)NH2: clinical utility and therapeutic development program.
20014 citationsauthor #1
Cleavage of disulfide-bridged stalk domains during shedding of angiotensin-converting enzyme occurs at multiple juxtamembrane sites.
200114 citationsauthor #6
Roles of the juxtamembrane and extracellular domains of angiotensin-converting enzyme in ectodomain shedding.
200118 citationsauthor #4
Treatment of hypoactive myocardium and diabetic cardiac myopathy with a GLP-1 peptide
20010 citationsauthor #1
Recombinant human GHRH (1–44) NH2
20011 citationsauthor #1
metabolic intervention with GLP-1 or its biologically active analogs to improve brain function with ischemia and reperfusion.
20000 citationsauthor #2
Shedding of somatic angiotensin-converting enzyme (ACE) is inefficient compared with testis ACE despite cleavage at identical stalk sites.
200075 citationsauthor #7
The role of complement receptor type 3 in the invasion strategies of Mycobacterium tuberculosis
19992 citationsauthor #1
Phorbol Ester-Induced Juxtamembrane Cleavage of Angiotensin-Converting Enzyme is not Inhibited by a Disulfide-Bridged Stalk
19991 citationsauthor #8
Phorbol ester-induced juxtamembrane cleavage of angiotensin-converting enzyme is not inhibited by a stalk containing intrachain disulfides.
199814 citationsauthor #7
ldentif ication of Mycobacterium tuberculosis signal sequences that direct the export of a leaderless P4actamase gene product in
19980 citationsauthor #5
Nonopsonic binding of Mycobacterium tuberculosis to complement receptor type 3 is mediated by capsular polysaccharides and is strain dependent
1997162 citationsauthor #4
Identification of phosphatidylinositol mannoside as a mycobacterial adhesin mediating both direct and opsonic binding to nonphagocytic mammalian cells
199776 citationsauthor #7
Identification of N-Linked Glycosylation Sites in Human Testis Angiotensin-converting Enzyme and Expression of an Active Deglycosylated Form*
199773 citationsauthor #5
Proteolytic release of membrane proteins: studies on a membrane-protein-solubilizing activity in CHO cells.
19979 citationsauthor #1
Proteolytic release of membrane-bound angiotensin-converting enzyme: role of the juxtamembrane stalk sequence.
199670 citationsauthor #1
Nonopsonic binding of Mycobacterium tuberculosis to human complement receptor type 3 expressed in Chinese hamster ovary cells
199693 citationsauthor #7
Biology of Mycobacterium tuberculosis and the Host-Pathogen Relationship
19950 citationsauthor #1
Medicine in the 21st century : genetic engineering and biotechnology
19930 citationsauthor #1
The functional role of tyrosine-200 in human testis angiotensin-converting enzyme.
19928 citationsauthor #2
The unique N-terminal sequence of testis angiotensin-converting enzyme is heavily O-glycosylated and unessential for activity or stability.
199249 citationsauthor #1
ANGIOTENSIN-CONVERTING ENZYME (ACE) IS A MARKER FOR PAPILLARY NEUROEPITHELIAL NEOPLASMS: 229
19900 citationsauthor #3
Single step affinity Chromatographic purification of human α-amylase from aspirated duodenal juice and its application in the measurement of pancreatic α-amylase synthesis rates in man
198913 citationsauthor #3
Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme.
1989265 citationsauthor #1
Angiotensin-converting enzyme: new concepts concerning its biological role.
1989390 citationsauthor #1
Site-directed inactivation of human lung acidic glutathione S-transferase by 1-chloro-2,4-dinitrobenzene in the absence of glutathione.
19896 citationsauthor #4
Single step affinity chromatographic purification of human alpha-amylase from aspirated duodenal juice and its application in the measurement of pancreatic alpha-amylase synthesis rates in man.
19891 citationsauthor #3
Catalysis of angiotensin I hydrolysis by human angiotensin-converting enzyme: effect of chloride and pH.
198835 citationsauthor #1
Synthesis of (1S)-N-(1-carboxy-5-aminopentyl)-glycylglycine - a prospective competitive inhibitor for angiotensin-converting enzyme
19861 citationsauthor #2
Purification of human lung and kidney angiotensin converting enzyme by a novel affinity technique
19860 citationsauthor #1
Molecular cloning of human testicular angiotensin-converting enzyme : The testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme ( polymerase chain reaction / alternative splicing )
year unknown0 citationsauthor #1
Chapter 11 Biochemical Markers of Rheumatoid Arthritis and Osteoarthritis : Clinical Utility and Practical Considerations
year unknown0 citationsauthor #1

TIMELINE

1986 1 citations

1988 35 citations

1989 675 citations

1990 0 citations

1992 57 citations

1993 0 citations

1995 0 citations

1996 163 citations

1997 320 citations

1998 14 citations

1999 3 citations

2000 75 citations

2001 56 citations

2002 78 citations

2003 524 citations

2004 6 citations

2005 41 citations

2006 36 citations

2007 10 citations

2008 4 citations

2009 16 citations

2011 28 citations

2012 346 citations

2013 728 citations

2014 251 citations

2015 343 citations

2016 414 citations

2017 133 citations

2018 61 citations

2021 0 citations

Unknown 0 citations

M. Ehlers

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT